Hefei Shell Pie Innovation Technology Co., Ltd.

MarTempo is a clinical-stage biotechnology company specializing in the development of innovative dermatological treatments using proprietary marine biological extracts. Founded in 2014 and headquartered in Hefei, China, the company leverages its 'Kapsun' platform—derived from mussel adhesive proteins—to create non-hormonal, natural alternatives for treating skin conditions such as atopic dermatitis, eczema, and pruritus. MarTempo's products are designed to repair the skin barrier and provide antibacterial and anti-inflammatory benefits without the side effects typically associated with corticosteroid therapies. The company maintains an active pipeline of therapeutic candidates and has established a strong commercial presence in the pediatric and sensitive skin care markets. Backed by investors like ABC Capital and Dingxin Capital, MarTempo aims to redefine dermatological care through marine-inspired biotechnology.